Forvis Mazars Wealth Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $297K | Sell |
2,353
-95
| -4% | -$12.5K | 0.01% | 374 |
|
|
2026
Q1 | $341K | Sell |
2,448
-25
| -1% | -$3.5K | 0.01% | 334 |
|
|
2025
Q4 | $304K | Buy |
2,473
+283
| +13% | +$34.4K | 0.01% | 351 |
|
|
2025
Q3 | $243K | Buy |
+2,190
| New | +$249K | ﹤0.01% | 376 |
|
|
2024
Q2 | – | Sell |
-3,355
| Closed | -$246K | – | 405 |
|
|
2024
Q1 | $246K | Sell |
3,355
-396
| -11% | -$30.5K | 0.01% | 368 |
|
|
2023
Q4 | $304K | Buy |
3,751
+296
| +9% | +$23K | 0.01% | 335 |
|
|
2023
Q3 | $259K | Sell |
3,455
-684
| -17% | -$52.6K | 0.01% | 346 |
|
|
2023
Q2 | $319K | Buy |
4,139
+969
| +31% | +$77.3K | 0.01% | 350 |
|
|
2023
Q1 | $263K | Buy |
3,170
+3
| +0.1% | +$248 | 0.01% | 358 |
|
|
2022
Q4 | $272K | Sell |
3,167
-507
| -14% | -$40.1K | 0.01% | 341 |
|
|
2022
Q3 | $227K | Sell |
3,674
-5
| -0.1% | -$315 | 0.01% | 359 |
|
|
2022
Q2 | $227K | Sell |
3,679
-133
| -3% | -$8.23K | 0.01% | 359 |
|
|
2022
Q1 | $227K | Buy |
3,812
+1,064
| +39% | +$68K | 0.01% | 278 |
|
|
2021
Q4 | $200K | Buy |
+2,748
| New | +$189K | 0.01% | 282 |
|
|
2021
Q3 | – | Sell |
-3,052
| Closed | -$210K | – | 274 |
|
|
2021
Q2 | $210K | Sell |
3,052
-1,959
| -39% | -$131K | 0.01% | 256 |
|
|
2021
Q1 | $324K | Sell |
5,011
-4,213
| -46% | -$272K | 0.02% | 216 |
|
|
2020
Q4 | $537K | Sell |
9,224
-5,594
| -38% | -$338K | 0.03% | 215 |
|
|
2020
Q3 | $936K | Sell |
14,818
-4,669
| -24% | -$324K | 0.05% | 142 |
|
|
2020
Q2 | $1.5M | Sell |
19,487
-1,631
| -8% | -$125K | 0.1% | 104 |
|
|
2020
Q1 | $1.58M | Sell |
21,118
-2,464
| -10% | -$170K | 0.13% | 84 |
|
|
2019
Q4 | $1.53M | Sell |
23,582
-20,828
| -47% | -$1.36M | 0.11% | 99 |
|
|
2019
Q3 | $2.81M | Buy |
44,410
+6,323
| +17% | +$413K | 0.23% | 63 |
|
|
2019
Q2 | $2.57M | Buy |
38,087
+59
| +0.2% | +$3.88K | 0.21% | 66 |
|
|
2019
Q1 | $2.47M | Buy |
38,028
+21,183
| +126% | +$1.41M | 0.21% | 68 |
|
|
2018
Q4 | $1.05M | Sell |
16,845
-15,595
| -48% | -$1.09M | 0.11% | 90 |
|
|
2018
Q3 | $2.5M | Buy |
32,440
+3,749
| +13% | +$283K | 0.22% | 63 |
|
|
2018
Q2 | $2.03M | Buy |
28,691
+3,434
| +14% | +$242K | 0.2% | 69 |
|
|
2018
Q1 | $1.9M | Buy |
25,257
+3,533
| +16% | +$281K | 0.19% | 70 |
|
|
2017
Q4 | $1.56M | Buy |
21,724
+13,326
| +159% | +$1.01M | 0.16% | 77 |
|
|
2017
Q3 | $680K | Buy |
+8,398
| New | +$642K | 0.07% | 113 |
|
|
2017
Q1 | – | Sell |
-2,870
| Closed | -$206K | – | 213 |
|
|
2016
Q4 | $206K | Buy |
2,870
+214
| +8% | +$15.9K | 0.03% | 197 |
|
|
2016
Q3 | $210K | Buy |
2,656
+230
| +9% | +$18.7K | 0.03% | 179 |
|
|
2016
Q2 | $202K | Sell |
2,426
-2,723
| -53% | -$242K | 0.03% | 182 |
|
|
2016
Q1 | $473K | Sell |
5,149
-289
| -5% | -$26.1K | 0.08% | 111 |
|
|
2015
Q4 | $550K | Buy |
5,438
+164
| +3% | +$17.1K | 0.08% | 106 |
|
|
2015
Q3 | $518K | Buy |
5,274
+1,640
| +45% | +$182K | 0.09% | 101 |
|
|
2015
Q2 | $425K | Buy |
3,634
+42
| +1% | +$4.59K | 0.06% | 116 |
|
|
2015
Q1 | $352K | Buy |
3,592
+665
| +23% | +$67.5K | 0.05% | 132 |
|
|
2014
Q4 | $276K | Buy |
2,927
+364
| +14% | +$37.6K | 0.05% | 132 |
|
|
2014
Q3 | $273K | Buy |
2,563
+50
| +2% | +$4.9K | 0.05% | 112 |
|
|
2014
Q2 | $208K | Buy |
+2,513
| New | +$196K | 0.04% | 136 |
|
Other funds holding GILD
Forvis Mazars Wealth Advisors's GILD Position: Q2 2026 in Review
Forvis Mazars Wealth Advisors reduced its Gilead Sciences (GILD) stake by 3.9% in Q2 2026, selling an estimated $12.5K and leaving 2,353 shares worth $297K. The position accounts for 0.01% of the portfolio, ranked #374.
Forvis Mazars Wealth Advisors first reported a position in GILD in Q2 2014 and has held it in 41 quarters since. The position peaked at $2.81M in Q3 2019. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Forvis Mazars Wealth Advisors held 2,353 shares of Gilead Sciences worth $297K as of Q2 2026.
- Forvis Mazars Wealth Advisors sold 95 Gilead Sciences shares in Q2 2026, an estimated $12.5K.
- Gilead Sciences made up 0.01% of Forvis Mazars Wealth Advisors's portfolio in Q2 2026, its #374 holding.
- Forvis Mazars Wealth Advisors first reported a position in Gilead Sciences in Q2 2014 and has held it in 41 quarters since.
- Forvis Mazars Wealth Advisors's Gilead Sciences position peaked at $2.81M in Q3 2019.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Forvis Mazars Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.